Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acne
Biotech
Pfizer’s $2.3B bet ends in failure as CD47 blocker scrapped
The Big Pharma has abandoned the second and final clinical-stage candidate from the Trillium acquisition.
James Waldron
May 5, 2026 9:15am
Ascletis prepares for China regulators after acne pill ph. 3 win
Jun 4, 2025 5:08am
Dermata's midstage rosacea study sees far-from-rosy results
Dec 5, 2022 11:11am
New study says the source of acne may be broken macrophages
Jul 26, 2022 6:00am
AnaptysBio's ACORN fails, marking end of acne program
Mar 15, 2022 7:45am
Skin fibroblasts play role in acne formation
Feb 22, 2022 8:40am
